Jul. 26 at 7:53 PM
$VKTX Well said. I DO think that the next "revolution" in weight loss drugs could well be VK2735 (a dual agonist with a longer half life than terzepatide and the better tolerability of a peptide), or a GLP1/GIP/Amylin triple agonist (depending on trials, since this hasn't been trialed yet).
Reta will be an important drug I think, but with its tolerability and other issues (e.g., tingling in extremities), it's most likely to be a niche drug for morbid obesity and perhaps body building. JMHO
